You are here
Emerald Health Therapeutics Announces Appointment of Pure Sunfarms President and CEO
Mandesh Dosanjh brings extensive consumer products experience with recent cannabis focus at Liquor Control Board of Ontario
VICTORIA, British Columbia, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (TSXV:EMH; OTCQX:EMHTF) (“Emerald”) and Village Farms International, Inc. (TSX:VFF) (OTC:VFFIF) today announced that Mandesh Dosanjh has been appointed President and Chief Executive Officer of Pure Sunfarms Corp., their 50/50 owned cannabis joint venture, effective on or before October 1, 2018. Mr. Dosanjh joins Pure Sunfarms from his position as Senior Vice President, Supply Chain and Wholesale, at the Liquor Control Board of Ontario (LCBO), where he led LCBO’s supply chain division, and developed and managed its supply chain and wholesale strategy as the LCBO prepared for the legalization of adult-use cannabis.
Mr. Dosanjh commented, “Over the past two years at the LCBO, I became immersed in the Canadian cannabis industry and gained an in-depth knowledge and understanding of its many suppliers. Pure Sunfarms truly stands out in the industry for both the experience and expertise of its team, and the quality of its growing operations, strongly positioning it for leadership in the adult-use market,” said Mr. Dosanjh. “I look forward to the opportunity to leverage my in-depth knowledge of the Canadian cannabis product landscape, as well as my many years managing consumer packaged goods supply chains, to drive the success of Pure Sunfarms as a fully integrated cannabis products business.”
“Mr. Dosanjh comes to Pure Sunfarms from a unique vantage point in the Canadian cannabis industry, and we expect his insights and relationships to be invaluable in growing the business,” said Mr. Chris Wagner, CEO, Emerald Health Therapeutics. “His broad experience will also be instrumental in driving efficiencies that will benefit bottom-line profit.”
“Mr. Dosanjh will be a tremendous asset to Pure Sunfarms as it moves aggressively to become a vertically integrated cannabis products supplier,” said Michael DeGiglio, CEO, Village Farms. “His deep experience in wholesale distribution and supply for large retailers, and intricate understanding of wholesale distribution in the Canadian cannabis industry, will provide Pure Sunfarms with a significant advantage in the development of its product and distribution strategy, as well as its brand and competitive positioning in the Canadian marketplace. In all respects, we are building this company the right way to drive sustainable value for the long term.”
Mr. Dosanjh is a seasoned supply chain executive with diverse industry experience. He has extensive experience planning and executing e-commerce, ERP, and logistics strategies focused on effectively and efficiently expanding business operations. His roles leading supply chains have provided him the opportunity to work closely with operations, quality control, IT, regulators, sales and marketing teams. As Senior Vice President, Supply Chain and Wholesale at LCBO, Mr. Dosanjh reported to the President and CEO. He was a member of the LCBO’s Executive Steering Committee for Cannabis, which provided guidance to the LCBO board of directors and Ontario government. Previously, Mr. Dosanjh held increasingly senior executive-level supply and distribution positions with a number of leading retailers, including Longo Brothers, Target Canada, Aritzia and Loblaw Companies.
About Village Farms International, Inc.
Village Farms International, Inc. is one of the largest and longest-operating vertically integrated greenhouse growers in North America and the only publicly traded greenhouse produce company in Canada. With more than 750 years of accumulated master grower experience coupled with advanced proprietary technology and environmentally sustainable growing practices, Village Farms is highly resource efficient. Village Farms produces and distributes fresh, premium-quality produce with consistency 365-days a year to national grocers in the U.S. and Canada from its large-scale Controlled Environment Agriculture (CEA) greenhouses in British Columbia and Texas, as well as from its partner greenhouses in BC, Ontario, and Mexico.
About Emerald Health Therapeutics, Inc.
Emerald Health Therapeutics (TSXV: EMH; OTCQX: EMHTF; Frankfurt: TBD) is licensed in Canada to produce and sell dried cannabis and cannabis oil for medical purposes. Emerald owns 50% of Pure Sunfarms, which is converting a licensed existing 1.1 million square foot greenhouse in Delta, BC and is now in commercial production. It owns Agro-Biotech, a Québec-based licensed cannabis grower with a 75,000 square foot indoor facility and is planning to add a 500,000 square foot greenhouse in Metro Vancouver. Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing value-added cannabis-based products with potential wellness and medical benefits. Emerald is part of the Emerald Health group, which is broadly focused on developing pharmaceutical, botanical, and nutraceutical products that may provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.
Please visit www.emeraldhealth.ca for more information or contact:
Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5
Ray Lagace, Investor Relations Manager
(800) 757 3536 Ext. #5
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined
in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such statements include legalization of nonmedicinal cannabis; production capacity of various facilities; expansion of facilities; and anticipated production costs.
We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, failure to obtain regulatory approvals; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.